Degradation of extracellular matrices (ECM) by proteolytic enzymes is a critical aspect of tumor metastasis. It has been shown that ECM degradation occurs at the cell surface and at the cell-matrix contacts of invading cancer cells. Therefore, cell surface localization of ECM-degrading enzymes facilitates tumor cell migration and invasion. Cell surface association of proteinases has also been shown to play a central role in the control of proteolytic activity by promoting the interaction of enzymes with receptors, activators, and relevant substrates. The matrix metalloproteinase-9 (MMP-9) is a key member of the MMP family of ECM-degrading enzymes that has been associated with malignant progression. Functional studies in the experimental models have shown a direct involvement of MMP-9 in tumor metastasis. Therefore, MMP-9 represents a promising target for novel anti-metastatic approaches. MMP-9 activity is regulated by the activation of the zymogen (proMMP-9) form into an active enzyme species capable of proteolytic activity. Although much information has been gained on the process of proMMP-9 activation in solution, the mechanisms yielding active MMP-9 in tumor cells are still poorly understood. New in vivo and in vitro evidence demonstrates that proMMP-9 binds with high affinity to the surface of tumor cells and localizes at the tumor-basement membrane junctions. Consistently, a surface-associated alpha2(IV) chain of collagen IV has been shown to mediate the binding of proMMP-9 to the surface of various tumor cell lines. Preliminary studies show that surface association of proMMP-9 enhances activation and catalytic activity while precluding interactions with TIMP-1, a specific MMP-9 inhibitor. However, the precise cellular and molecular mechanisms mediating these effects remain to be determined. Studies designed in this application will (1) define the proteolytic mechanisms leading to proMMP-9 activation in tumor cells, (2) establish the structural basis for the cell surface association of proMMP-9, (3) define the role of alpha2(IV) in the cell surface binding and activation of proMMP-9 and (4) investigate the role of cell surface association and activation of proMMP-9 on ECM degradation and tumor cell invasion. The results of these studies will address a new paradigm in the regulation of proMMP-9 activation and may provide novel and specific tools to inhibit MMP-9 activity in human tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082298-02
Application #
6173604
Study Section
Pathology B Study Section (PTHB)
Program Officer
Ault, Grace S
Project Start
1999-07-01
Project End
2004-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
2
Fiscal Year
2000
Total Cost
$248,781
Indirect Cost
Name
Wayne State University
Department
Pathology
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Dong, Zhong; Bonfil, R Daniel; Chinni, Sreenivasa et al. (2005) Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166:1173-86
Brown, Stephen; Meroueh, Samy O; Fridman, Rafael et al. (2004) Quest for selectivity in inhibition of matrix metalloproteinases. Curr Top Med Chem 4:1227-38
Toth, Marta; Chvyrkova, Irina; Bernardo, M Margarida et al. (2003) Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 308:386-95
Fridman, Rafael; Toth, Marta; Chvyrkova, Irina et al. (2003) Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 22:153-66
Rosenblum, Gabriel; Meroueh, Samy O; Kleifeld, Oded et al. (2003) Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J Biol Chem 278:27009-15
Liu, Xu-Wen; Bernardo, M Margarida; Fridman, Rafael et al. (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278:40364-72
Kotra, Lakshmi P; Zhang, Li; Fridman, Rafael et al. (2002) N-Glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9. Bioorg Chem 30:356-70
Nemeth, Jeffrey A; Yousif, Rafid; Herzog, Michael et al. (2002) Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94:17-25
Bernardo, M Margarida; Brown, Stephen; Li, Zhi-Hong et al. (2002) Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 277:11201-7
Kleifeld, O; Kotra, L P; Gervasi, D C et al. (2001) X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme. J Biol Chem 276:17125-31

Showing the most recent 10 out of 13 publications